Medical Microinstruments Raises $125M for Symani Expansion

A hospital's first robotic microsurgery case arrives after the simulations, the instrument handling and the conversations about who will support the team. Medical Microinstruments, or MMI, is financing more of that work with a $125M Series D announced on October 8, 2026, led by existing investor BioStar Capital.

S3 Ventures, Angelini Ventures, an undisclosed strategic corporate investor and existing backers participated. Jacksonville-based MMI makes the Symani Surgical System for surgeon-controlled open microsurgery and reports approximately 50 installations and 3,500 procedures worldwide. The funding supports U.S. and international commercial expansion, clinical evidence and further development of the platform.

For hospitals, Symani introduces a precision tool together with an ongoing relationship with its manufacturer. MMI's published training, clinical support and maintenance offerings show how much of robotic adoption takes place around the machine. The Series D gives that surrounding organization a larger budget while researchers explore applications with a much longer evidence horizon.

How MMI built a company around a miniature wrist

MMI began near Pisa, Italy, in 2015. In a direct interview with Jacobacci & Partners, cofounder Massimiliano Simi described founding the business with Giuseppe Prisco and Hannah Teichmann after work on miniaturizing an articulated surgical wrist. The engineering question was intimate: how could an instrument move with useful dexterity inside anatomy smaller than a millimeter?

Simi remains MMI's CTO. CEO Mark Toland brings experience leading Corindus and working at Boston Scientific, connecting the company's engineering origin to the work of commercializing medical equipment. That combination matters in a market where a promising instrument still needs an operating environment, trained users and dependable support.

Symani combines NanoWrist microinstruments with tremor reduction and motion scaling. Its technical overview describes how a surgeon's larger hand movements become smaller instrument movements, while articulated tips support delicate manipulation. The surgeon continues to direct the procedure; the robot changes the scale at which the surgeon can work.

The design sits alongside the hospital's imaging choices. MMI says Symani is compatible with traditional optical microscopes, hybrid microscopes and 3D exoscopes, giving teams ways to integrate the equipment into their operating rooms. For a clinical buyer, that compatibility brings the discussion back to the people and equipment already involved in a case, rather than an isolated demonstration of robotic dexterity.

What the Series D finances beyond installation

BioStar Capital's return as lead investor follows several earlier rounds. MMI's current funding snapshot places total investment to date at approximately $345M, including the new financing. The company raised a $110M Series C led by Fidelity Management & Research Company in 2024; earlier funding supported product development, trials and commercialization.

The roughly 50 systems and 3,500 procedures disclosed with the Series D are company-reported adoption figures. They establish that Symani has moved into clinical use, while leaving important commercial details open: MMI did not disclose revenue, system pricing, utilization by installation or valuation in this announcement. A hospital procurement team will need its own assessment of how the equipment fits the procedures and resources it expects to provide.

MMI's hospital program offering makes the implementation work visible. Training includes instruction, simulation and onsite support; clinical specialists help with cases and troubleshooting. The Symani365 service program covers technical support, maintenance and repairs, extending the relationship past delivery of the hardware.

Those services make program development a useful lens for interpreting the financing. Expanding the installed base also expands the number of teams that need training, the systems that need service and the cases from which clinical experience can accumulate. Investors are financing an organization capable of carrying those relationships across more hospitals, alongside the engineering of energy instruments and digital surgery capabilities described as future development areas.

Regulatory scope and the separate REMIND research path

Symani received FDA De Novo authorization in April 2024 and carries CE marking in Europe. The FDA's K250014 instrument summary describes specified adult open microsurgery uses involving small blood vessels and lymphatic ducts, including free-flap surgery of the breast and extremities and lymphatic surgery of the extremities. Indications differ across regions, so a broad reference to surgical robotics needs that clinical specificity.

MMI is also investigating an application involving cervical lymphatic drainage in Alzheimer's patients with confirmed lymphatic abnormalities. The July 30 REMIND update reported FDA approval of an Investigational Device Exemption supplement following review of initial 30-day safety data. That allowed enrollment to expand toward a full early feasibility population of 15 patients.

REMIND is collecting safety and feasibility information. Symani's safety and effectiveness for lymphatic reconstruction in brain disease have not been established by the FDA, and this use remains investigational. Permission to expand an early study therefore belongs to a different decision process from authorization to sell a device for its established surgical indications.

The Series D connects commercial expansion with the cost of learning where the technology may be useful next. For Toland and Simi, those activities put different demands on the same company: support hospitals using today's instruments, improve the platform and preserve the time and discipline needed for new clinical evidence. As more hospitals build Symani programs, the clinical relationship surrounding each miniature instrument will continue to grow through training rooms, operating rooms and the research those teams help make possible.